Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)
- 11 August 2021
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 107 (6) , 602-608
Abstract
Background: Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple‐class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of the KCd on triple‐class RRMM patients at our institution.Patients and Methods: Twenty‐three patients with triple‐class RRMM treated with KCd between June 2017 and October 2020 were included in our analysis. The regimen KCd consisted of 28 days cycles of carfilzomib 20/36 mg/m2 IV on days 1, 2, 8, 9, 15, and 16, cyclophosphamide 300 mg/m2 IV weekly, and dexamethasone (20‐40) mg orally weekly.Results: Patients received a median of 6 (3‐10) prior regimens. The median number of cycles administered was 4 (1‐11) cycles. Overall response rate was 52%, 6 patients (26%) achieved very good partial response (VGPR), 6 patients (26%) achieved partial response (PR), and 5 patients (22%) achieved stable disease (SD). Progression‐free survival (PFS) and Overall‐survival (OS) were 4 and 11.9 months, respectively. There was no reported treatment‐related mortality. The most common grade ≥3 adverse events were neutropenia (26%), thrombocytopenia (56.5%), and anemia (56.5%).Conclusions: KCd showed clinically meaningful efficacy and manageable safety profile in patients with triple‐class RRMM in real‐world.Keywords
This publication has 20 references indexed in Scilit:
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyThe Lancet Oncology, 2020
- Treatment of relapsed multiple myeloma: Evidence-based recommendationsBlood Reviews, 2020
- Relapsed refractory multiple myeloma: a comprehensive overviewLeukemia, 2019
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Multiple myeloma: an overview of managementPalliative Care and Social Practice, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialThe Lancet Oncology, 2017
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- Modeling Survival Data: Extending the Cox Model2000